Skip to main content
Clinical Trials/JPRN-UMIN000052764
JPRN-UMIN000052764
Not yet recruiting
未知

Development of a biomarker for predicting the clinical effectiveness of tezepelumab in patients with severe asthma and elucidation of immunomodulatory effects of tezepelumab - Tokyo Asthma Study for Tezepelumab: TOAST2

Juntendo University School of Medicine0 sites60 target enrollmentNovember 20, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
bronchial asthma
Sponsor
Juntendo University School of Medicine
Enrollment
60
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 20, 2023
End Date
April 1, 2027
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Juntendo University School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Subjects with malignancy Current smokers and subjects with a history of smoking within the past 6 months Subjects receiving treatment with other biologics and less than 1 month since last administraion (benralizumab requires 2 months) Subjects who have received bronchial thermoplasty within the past 6 months Subjects with a history of anaphylaxis due to biologics Subjects currently pregnant or breastfeeding Subjects with chronic obstructive pulmonary disease with obvious emphysematous changes Subjects with hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, pulmonary hypertension, sequelae of tuberculosis, diffuse panbronchiolitis, and interstitial pneumonia

Outcomes

Primary Outcomes

Not specified

Similar Trials